PHISO-SCRUB
LOE ApproachingNDATOPICALSPONGE
Approved
Aug 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHISO-SCRUB is a topical sponge formulation approved in 1977 as a small-molecule NDA product sponsored by Sanofi. The specific indication, mechanism of action, and active pharmaceutical ingredient are not disclosed in available data. This legacy product represents a mature, established therapeutic option in its category.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30), indicating defensive positioning and potential team restructuring or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PHISO-SCRUB currently has zero linked job openings, reflecting its mature lifecycle status and approaching loss of exclusivity. Careers in this product are concentrated in commercial roles focused on defending market share and managing the transition to generic competition.
Brand ManagerField Sales Representative
Worked on PHISO-SCRUB at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.